Research.Patient.info
FLT3-mutated Acute Myeloid Leukemia research hub
2 indexed studies · 0 currently recruiting
- authorisedPhase I and Phase II (Integrated)- Other
Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN
This study is looking at a new way to treat a type of blood cancer called FLT3-mutated Acute Myeloid Leukaemia. It combines standard treatments with a new medicine called venetoclax to see if it's safe and helps more people get better without the cancer coming back.
France - active not recruitingPHASE2
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
This study is testing a new combination of treatments for children and teenagers with a certain type of acute myeloid leukemia (FLT3-mutated AML). It combines a drug called midostaurin with standard chemotherapy to see if it's safe and effective for these patients.
Czechia · Germany · Italy